GlassScriptPhysician profile
Kenneth C Obiaja
NPI 1639342363
$3,300.00
in general payments reported to CMS, 2019-2025
24 companies · $1,287 in 2025
The $1,287 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $474 · 2020: $128 · 2021: $160 · 2022: $35.67 · 2023: $572 · 2024: $645 · 2025: $1,287.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,503.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,503.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $406.62 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Exact Sciences Corporation | $397.48 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boston Scientific Corporation | $378.76 | 2023-2025 | S-Icd System Magnet, Rhythmia Mapping System, Watchman Flx |
| Astrazeneca Pharmaceuticals LP | $340.53 | 2020-2025 | Breztri, Airsupra, Farxiga |
| Pfizer INC. | $289.08 | 2020-2025 | |
| Amgen INC. | $271.56 | 2019-2025 | Otezla, Repatha, Repatha |
| Lilly USA, LLC | $240.97 | 2023-2025 | Mounjaro, Zepbound, Kisunla |
| Glaxosmithkline, LLC. | $221.84 | 2019-2025 | Shingrix, Trelegy Ellipta |
| Tosoh Bioscience, INC. | $169.00 | 2019 | |
| Abbvie INC. | $141.04 | 2024-2025 | |
| Astellas Pharma US INC | $118.53 | 2019 | |
| Abbott Laboratories | $63.59 | 2021-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Amarin Pharma, INC. | $47.94 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.97 | 2024-2025 | Xifaxan |
| Kowa Pharmaceuticals America, INC. | $28.44 | 2019-2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Si-Bone, INC. | $23.70 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.45 | 2021 | |
| Novartis Pharmaceuticals Corporation | $18.70 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $17.09 | 2019 | |
| Idorsia Pharmaceuticals US INC | $14.44 | 2023 | Quviviq |
| Welch Allyn | $14.08 | 2021 | |
| Merck Sharp & Dohme LLC | $13.58 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.52 | 2025 | Caplyta |
| Allergan, INC. | $12.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Obiaja listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.